多种维生素的使用和癌症幸存者的全因和因特定死亡率
Yikyung Park1, Zeinab Farhat2, Linda M Liao2
1Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA. yikyungpark@wustl.edu.
British journal of cancer
|November 28, 2023
概括
多种维生素的使用对大多数癌症幸存者来说没有显著的生存益处. 然而,一些癌症幸存者可能会经历适度的生存优势,特别是那些患有特定癌症类型的人. 建议与医疗保健提供者进行进一步讨论.
科学领域:
- 在瘤学瘤学.
- 营养流行病学 营养流行病学
- 公共卫生 公共卫生
背景情况:
- 癌症幸存者经常使用多种维生素进行自我护理,尽管对其益处和危害的证据有限.
- 这项研究研究了多种维生素使用与癌症幸存者死亡风险之间的关联.
研究的目的:
- 为了检查多维生素消费与癌症幸存者的大量队列中的死亡结果之间的关系.
- 为了确定与复合维生素相关的潜在生存益处或风险,使用癌症后诊断.
主要方法:
- 在NIH-AARP饮食和健康研究中分析了15936名男性和7026名女性癌症幸存者的数据.
- 在癌症诊断后大约4.6年,评估多种维生素的使用类型和频率.
- 使用Cox比例危险回归模型来估计多变量调整的相对风险 (RR) 和95%置信区间 (CI).
主要成果:
- 多种维生素的使用与男性或女性癌症幸存者的全因死亡率降低无关.
- 在女性生殖癌幸存者和男性非生殖癌幸存者中,观察到心血管疾病 (CVD) 死亡率的适度逆相关性.
- 多种维生素的使用与皮肤和乳腺癌幸存者的癌症特异性死亡风险较低相关.
结论:
- 多种维生素的使用可能为某些癌症幸存者群体提供适度的生存益处.
- 医疗保健提供者应与癌症幸存者就多维生素补充剂的潜在益处和危害进行讨论.
相关概念视频
Cancer Survival Analysis
356
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
356
Cancer Prevention
6.2K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
6.2K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cancer Vaccines
376
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
376
Kaplan-Meier Approach
152
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
152
Comparing the Survival Analysis of Two or More Groups
197
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
197


